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Abstract
Background Laparoscopic surgery for colon cancer is
associated with improved recovery and similar cancer
outcomes at 3 and 5 years in comparison with open sur-
gery. However, long-term survival rates have rarely been
reported. Here, we present survival and recurrence rates of
the Dutch patients included in the COlon cancer Laparo-
scopic or Open Resection (COLOR) trial at 10-year follow-
up.
Methods Between March 1997 and March 2003, patients
with non-metastatic colon cancer were recruited by 29
hospitals in eight countries and randomised to either
laparoscopic or open surgery. Main inclusion criterion for
the COLOR trial was solitary adenocarcinoma of the left or
right colon. The primary outcome was disease-free survival
at 3 years, and secondary outcomes included overall sur-
vival and recurrence. The 10-year follow-up data of all
Dutch patients were collected. Analysis was by intention-
to-treat. The trial was registered at ClinicalTrials.gov
(NCT00387842).
Results In total, 1248 patients were randomised, of which
329 were Dutch. Fifty-eight Dutch patients were excluded
and 15 were lost to follow-up, leaving 256 patients for
10-year analysis. Median follow-up was 112 months. Dis-
ease-free survival rates were 45.2 % in the laparoscopic
group and 43.2 % in the open group (difference 2.0 %;
95 % confidence interval (CI) -10.3 to 14.3; p = 0.96).
Overall survival rates were 48.4 and 46.7 %, respectively
(difference 1.7 %; 95 % CI -10.6 to 14.0; p = 0.83).
Stage-specific analysis revealed similar survival rates for
both groups. Sixty-two patients were diagnosed with
recurrent disease, accounting for 29.4 % in the laparo-
scopic group and 28.2 % in the open group (difference
1.2 %; 95 % CI -11.1 to 13.5; p = 0.73). Seven patients
had port- or wound-site recurrences (laparoscopic n = 3
vs. open n = 4).
Conclusions Laparoscopic surgery for non-metastatic
colon cancer is associated with similar rates of disease-free
survival, overall survival and recurrences as open surgery
at 10-year follow-up.
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Laparoscopic surgery for colon cancer has proven to result in
short-term benefits compared to open surgery, such as
reduced blood loss, less post-operative pain and shorter
length of hospital stay [1–3]. However, there are few studies
on long-term outcomes of laparoscopic and open surgery for
colon cancer [4–7]. This is remarkable, as malignancy of the
colon and rectum is the third most common malignancy
worldwide, accounting for approximately 1,361,000 new
patients and 694,000 deaths every year [8].
Early detection of recurrent colon cancer is important
because promptmanagement of these recurrences is associated
with improved survival [9]. Current colon cancer guidelines
advocate follow-up up to 5 years after surgery. [9, 10] Never-
theless, knowledgeof the course of disease beyond theperiodof
5 years is limited. Therefore, it remains unclear whether lim-
iting follow-up to 5 years post-operatively is sufficient.
The COlon cancer Laparoscopic or Open Resection
(COLOR) trial was designed as an international multicen-
tre randomised trial to demonstrate non-inferiority of
laparoscopic surgery for colon cancer compared with the
conventional open resection [11]. Previously, 3- and 5-year
results have been published, and similar survival outcomes
for both groups were reported [12]. Here, we present the
long-term outcomes of Dutch patients included in the
COLOR trial at 10-year follow-up.
Materials and methods
Study design
The COLOR trial is a randomised, non-inferiority, open-
label trial. Between March 1997 and March 2003, patients
were recruited by 29 hospitals in eight countries. The trial
was approved by the ethics committee of each participating
hospital. Because 10-year follow-up was not included in
the initial COLOR trial protocol, the study had to be re-
opened in all participating countries separately. The
Netherlands is a relative small country and its geography
made it possible to accurately check all medical records
and collect all data. Therefore, only data of Dutch patients
were used for this study. The Ethical Committee of VUmc
approved 10-year follow-up of all Dutch patients. This trial
is registered at ClinicalTrials.gov, number NCT00387842.
Participants
The main criterion for inclusion in the COLOR trial was
non-metastatic solitary adenocarcinoma of the caecum,
ascending colon, descending colon, or sigmoid colon above
the peritoneal deflection. Tumours of the transverse colon
or splenic flexure were not included in this study because
laparoscopic surgery of these tumours was considered
technically more challenging and prone to conversion to
open surgery. Diagnosis was to be made by barium enema
radiography or colonoscopy. A biopsy was required in
polyps, not in macroscopically evident adenocarcinomas.
Metastatic disease was excluded by radiological imaging of
the chest and liver. Exclusion criteria were: body mass
index [30, distant metastases, multiple primary colon
tumours, invasion of adjacent structures, signs of obstruc-
tion, previous ipsilateral surgery of the colon, history of
malignant disease (with the exception of curative treatment
for basal cell carcinoma of the skin or in situ carcinoma of
the cervix) and absolute contraindication for general
anaesthesia or pneumoperitoneum. All patients gave writ-
ten informed consent.
Randomisation and masking
Eligible patients were assigned to either laparoscopic
resection or open resection at random in a 1:1 ratio and
stratified according to participating centre and type of
resection. Randomisation was performed by the trial
coordinator (RV, who was succeeded by EK) at Erasmus
University Medical Center, Rotterdam, Netherlands, and
allocation was performed by telephone or fax. Neither
patients nor caregivers were blinded to the result of
randomisation.
Procedures
Patients in both groups had the same extent of resections:
in right hemicolectomy a resection of the caecum,
ascending colon and hepatic flexure, in left hemicolectomy
a resection with a margin of at least 5 cm below and 5 cm
above the lesion and in sigmoidectomy a resection of the
sigmoid of at least 5 cm below and 5 cm above the lesion.
Pre- and post-operative care and adjuvant treatment were
applied according to local protocols.
Follow-up for both groups was required at least once a
year during the first 5 post-operative years and included
colon, liver and thorax imaging studies at 3-year follow-up.
After 5 years, further follow-up was at the surgeon’s dis-
cretion. Participating centres treated detected recurrences
according to local protocols, including resection and
chemotherapy.
Surgical teams had performed at least 20 laparoscopi-
cally assisted colectomies and had to submit an unedited
videotape of a laparoscopically assisted colectomy to
assess safety of surgical techniques before entering the
trial. Patients in the laparoscopic group could be converted
preoperatively to an open resection if there was
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malfunctioning equipment or if no surgeon with laparo-
scopic skills was available. All converted patients, i.e.
preoperative and intraoperative, remained in the laparo-
scopic group for analysis based on intention-to-treat
principle.
Outcomes
The primary outcome was disease-free survival at 3 years,
which has been reported earlier [12]. Secondary outcomes
included overall survival and pattern of recurrence.
Recurrences were defined as local or distant. Furthermore,
we defined local recurrence as recurrence at the surgical
site or port- or wound-site and distant recurrence as all
other recurrences. When no clinical signs of recurrence
were present at 10-year follow-up, further imaging was not
done and the patient was considered as not having recurrent
disease. For 10-year follow-up results, data of all Dutch
patients were collected. The hospital information system
was used to collect details at 10 years after index surgery
and when no information was available, the general prac-
titioner of the patient was consulted. If information about
survival of the patients was missing, the Municipal Per-
sonal Records Database was checked.
Statistical analyses
Analyses were performed according to the intention-to-
treat principle. Baseline characteristics were compared by
using Student’s t test or a Mann–Whitney U test for
numerical variables and a Chi-square test or an exact test
where necessary. The Kaplan–Meier method was used to
calculate the median follow-up period [13] and 10-year
disease-free survival, overall survival and recurrence rates.
Survival was calculated as time from surgery to last date of
follow-up or date of death. IBM SPSS version 22 was used
for statistical analyses.
Results
Patients
In total, 1248 patients were randomly assigned to either
laparoscopic resection or conventional open resection, of
which the six participating Dutch centres recruited 329. Of
the Dutch patients, 58 were excluded for various reasons
(Fig. 1). The first patient inclusion in the Netherlands was
at 21 March 1997 and the last at 10 March 2003. In
November 2014 collecting of 10-year follow-up data was
started. In the laparoscopic and open group, six and nine
patients, respectively, had been lost to follow-up, leaving
256 patients for 10-year analysis. Of those, 125 patients
were assigned to be operated laparoscopically and 131
patients to be operated through an open procedure (Fig. 1).
The median follow-up of all patients was 112 months in
the laparoscopic group (range 0.03–198.92) and
111 months in the open group (range 0.10–194.89)
(p = 0.83). Median follow-up of survivors was
156 months in the laparoscopic group (range
117.97–198.92) and 150 months in the open group (range
105.11–194.13).
Baseline characteristics showed no significant differ-
ences between the two groups (Table 1). Operative and
pathological data showed no differences except for length
of operative procedure, which was longer in the laparo-
scopic group (140 vs. 95 min, p\ 0.001) and blood loss,
which was less in the laparoscopic group (113 vs. 200 mL,
p = 0.02). Distribution of disease stage and size of tumour
was similar in both groups (Table 2).
Conversion
Of 125 patients who were assigned to undergo a laparo-
scopic procedure, conversion to open surgery was per-
formed in 40 patients (32 %). In six patients, the decision
for conversion was made preoperatively (poor cardiac
condition (n = 3), randomisation error (n = 1), extensive
T4 tumour (n = 1) and unknown (n = 1)). In 34 patients
(27 %), conversion was performed during the operation,
reasons for conversion were fixation of the tumour
(n = 10), adhesions (n = 3), the tumour could not be
identified (n = 8), macroscopic metastases were found
(n = 2), other reasons (n = 10), and in one patient, the
reason was unknown.
Disease-free survival
The disease-free survival rate at 10 years post-operatively
was 45.2 % in the laparoscopic group and 43.2 % in the
open group (difference 2.0 %; 95 % confidence interval
(CI) -10.3 to 14.3; p = 0.96). In patients with stage I
colon cancer, disease-free survival rates were 54.8 and
45.9 % for the laparoscopic and open group, respectively
(difference 8.9 %; 95 % CI -16.2 to 34.0; p = 0.52). In
patients with stage II disease, these rates were 48.1 and
35.7 % (difference 12.4 %; 95 % CI -5.9 to 30.7;
p = 0.22) and in patients with stage III disease 34.2 % in
the laparoscopic group and 52.5 % in the open group
(difference -18.3 %; 95 % CI -39.9 to 3.3; p = 0.09)
(Fig. 2).
Overall survival
At 10-year follow-up, 133 patients had died, 64 in the
laparoscopic group and 69 in the open group. Fifty-three
Surg Endosc (2017) 31:2607–2615 2609
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Fig. 1 Trial profile
Table 1 Patient baseline characteristics
Laparoscopic colectomy (n = 131) Open colectomy (n = 140) Total (n = 271)
Age (years), median (range) 71 (54–84) 72 (54–84) 71 (54–84)
Gender, n (%)
Male 63 (48.1) 76 (54.3) 139 (51.3)
Female 68 (51.9) 64 (45.7) 132 (48.7)
ASA group, n (%)
I 44 (33.6) 49 (35.0) 93 (34.3)
II 62 (47.3) 73 (52.1) 135 (49.8)
III 20 (15.3) 18 (12.9) 38 (14.0)
Missing data 5 (3.8) – 5 (1.8)
Body mass index (kg/m2), median (range) 24.8 (20.2–29.6) 25.1 (20.2–30.7) 24.9 (20.2–29.9)
Range 10th to 90th percentile, ASA American society of anesthesiologists classification
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patients who died had recurrent disease (27 patients in the
laparoscopic group and 26 patients in the open group). The
10-year overall survival rate was 48.4 % in the laparo-
scopic group and 46.7 % in the open group (difference
1.7 %; 95 % CI -10.6 to 14.0; p = 0.83). In patients with
stage I colon cancer, overall survival rates were 58.1 and
52.7 % for the laparoscopic and open group, respectively
(difference 5.4 %; 95 % CI -19.7 to 30.5; p = 0.67). In
patients with stage II disease, these rates were 51.9 and
41.1 % (difference 10.8 %; 95 % CI -7.8 to 29.4;
p = 0.23) and in patients with stage III disease 36.8 % in
the laparoscopic group and 50.8 % in the open group
(difference -14.0 %; 95 % CI -35.8 to 7.8; p = 0.22)
(Figure as Supplementary material).
Recurrences
A total of 62 patients developed recurrent disease during the
10-year follow-up period, accounting for a recurrence rate of
29.4 % in the laparoscopic group and 28.2 % in the open
group (difference 1.2 %; 95 % CI -11.1 to 13.5; p = 0.73).
In patients with stage I colon cancer, recurrence rates were
19.8 and 22.5 % for the laparoscopic and open group,
respectively (difference -2.7 %; 95 % CI -25.2 to 19.8;
p = 0.80). In patients with stage II disease, these rates were
21.8 and 27.3 % (difference-5.5 %; 95 % CI -23.7 to 12.7;
p = 0.65) and in patients with stage III disease 46.8 % in the
laparoscopic group and 35.4 % in the open group (difference
11.4 %; 95 % CI -11.6 to 34.4; p = 0.29) (Fig. 3).
The site of recurrence did not significantly differ
between the two groups. In total, 43 patients suffered a
locoregional recurrence, 23 patients in the laparoscopic
group and 20 patients in the open group. Seven patients had
a recurrence in the port- or wound-site, three patients in the
laparoscopic and four patients in the open group. The time
of occurrence of the port- and wound-site recurrences after
surgery was in the laparoscopic group 8.1, 30.9 and
34.7 months and in the open group 16.0, 16.7, 27.5 and
31.2 months. In total, 40 patients were diagnosed with a
distant recurrence (19 in the laparoscopic and 21 in the
open group), accounting for 69 distant recurrences
(Table as Supplementary material).
At 5 years follow-up, 154 patients were alive and free of
disease. Between 5 and 10 years after surgery five of these
154 patients (3 %) developed a first recurrence. Three other
patients developed a recurrence between 5 and 10 years
after surgery as well, and however, in these patients it was
not the first recurrence.
Table 2 Operative and pathological data
Laparoscopic colectomy (n = 125) Open colectomy (n = 131) Total (n = 256) p value
Intervention, n (%) 0.527a
Right hemicolectomy 68 (54.4) 66 (50.4) 134 (52.3)
Left hemicolectomy 10 (8.0) 10 (7.6) 20 (7.8)
Sigmoidectomy 41 (32.8) 52 (39.7) 93 (36.3)
Other 6 (4.8) 3 (2.3) 9 (3.5)
Conversions
Preoperative 6 (4.8) –
Intraoperative 34 (27.2) –
Duration of intervention (min), median (range)
In theatre 180 (130–270) 135 (93.5–210) \0.001b
Skin to skin 140 (95–229.5) 95 (70–160.2) \0.001b
Blood loss (ml), median (range) 112.5 (13.5–559) 200 (50–825) 0.024b
Size of tumour (cm), median (range) 4.0 (2.0–6.8) 4.0 (2.5–7.5) 0.168c
Resection margins, n (%) 1.00a
Positive 1 (0.8) 2 (1.5)
Negative 117 (99.2) 128 (98.5)
Tumour stage, n (%) 0.974a
I 31 (25.0) 30 (23.4) 61 (24.2)
II 54 (43.5) 57 (44.5) 111 (44.0)
III 39 (31.5) 41 (32.0) 80 (31.7)
Range 10th to 90th percentile
a Fisher’s exact test
b Mann–Whitney U test
c Student’s t test
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Discussion
The survival and recurrence rates 10 years after either
laparoscopic or open colectomy for cancer are similar. At
10 years after surgery for stage I, II and III colon cancer,
disease-free survival rates were 45.2 and 43.2 % in,
respectively, the laparoscopic and open group. Overall
survival rates were 48.4 and 46.7 % for the laparoscopic
and open group. Lacy et al. [4] reported in 219 patients
with colon cancer stage I–III at a median follow-up of
95 months similar cancer-free survival and overall survival
rates between the laparoscopic and open groups as well.
Due to reduction in surgical trauma, minimally invasive
surgery was expected to be associated with improved
oncological outcomes [14]. However, this assumption has
not been validated by current available evidence.
Only 3 % of all patients that were free of disease and
alive at 5 years developed a recurrence more than 5 years
after index surgery. Merely two other studies on long-term
survival after colon cancer surgery have been published.
Similar patterns of recurrences were reported, but exact
numbers were not provided [4, 5]. Hence, the current colon
cancer guidelines recommendation to cease follow-up after
5 years after surgery appears justified.
The intraoperative conversion rate of this substudy was
27 %, which is higher than the 17 % overall intraoperative
conversion rate of the COLOR trial. Other large ran-
domised trials reported conversion rates of 11, 15, 21 and
25 % [3, 15–17]. All these trials were conducted between
1993 and 2005. In those years, routine preoperative
imaging of colonic cancer was limited in most patients to
barium enema and ultrasonography of the liver [2, 14, 15].
Fig. 2 Disease-free survival. A All stages, B stage I, C stage II and D stage III
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In the COLOR trial, imaging of the tumour was performed
with computed tomography (CT) in 4 % of the patients and
with barium enema in 40 % of the patients. In 81 % of the
patients, a colonoscopy was done with tattooing of the
tumour in 3 % [2]. Nowadays, abdominal CT has become a
standard component of the diagnostic workup in patients
with colon cancer allowing preoperative identification of
patients with large and invasive colonic carcinomas which
are not amenable to laparoscopic surgery. In this study, the
reason for conversion was fixation of the tumour in one-
third of the patients, and in one-fourth, the tumour could
not be properly identified during the procedure, both as
result of limitations in preoperative workup at the time this
trial was conducted. The high rate of converted procedures
may have been caused by limited technical skills among
the surgeons, as well as deficiencies in the workup at that
time, such as quality of the CT scan and lack of inking of
the tumour at endoscopy, which was not part of the stan-
dard preoperative procedure at that time.
Even though in this report all converted patients were
analysed in the laparoscopic group according to the
intention-to-treat principle, survival rates of the laparo-
scopic and open group did not differ. However, the impact
of conversion on survival remains unclear. A recent report
on 104,400 patients included in the American National
Cancer Database concluded that conversion from laparo-
scopic to open surgery did not result in compromised
oncologic outcomes [18]. On the contrary, the CLASICC
trial showed worse overall survival in converted patients at
a median follow-up of 63 months [5].
Deposits of tumour cells at trocar sites (port-site
metastases) were reported during the initial experience
with laparoscopic colectomy for cancer [19, 20]. These
findings stalled implementation of laparoscopic surgery in
Fig. 3 Recurrence. A All stages, B stage I, C stage II and D stage III
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the management of colon cancer for more than a decade. In
this study, cancer recurrences in the abdominal wall were
noted within 10 years after surgery in 2 % of patients. All
these recurrences occurred within 3 years after index sur-
gery. In the CLASICC trial, 12 out of 641 (1.9 %) analysed
patients had one or more port- or wound-site recurrences,
ten (2.3 %) in the laparoscopic group and two (0.9 %) in
the open group, without a significant difference [5]. The
COST trial reported among 863 analysed patients, surgical
wound metastases as first site of recurrence in four patients
(0.9 %) in the laparoscopic group and two patients (0.5 %)
in the open group at 5 years [21].
This report has several limitations. Firstly, follow-up
until 10 years after index surgery was not part of the
original protocol for the COLOR trial. This report only
involves the Dutch patients of the COLOR trial repre-
senting one quarter of the entire study population.
Although only a subgroup of patients was included, this
study on long-term outcomes after colon cancer surgery
involves one of the largest cohorts of patients reported to
date. Furthermore, the primary outcome of the original
study was disease-free survival at 3 years. This study was
not powered for a 10-year follow-up period, and the
number of patients must have been larger according to an
adequate power analysis. Therefore, results as the high
conversion rate of the Dutch population compared to the
entire cohort should be interpreted with caution.
In conclusion, disease-free survival, overall survival and
recurrence rates at 10-year follow-up after laparoscopic
and open resection of non-metastatic and non-invasive
colon cancer were similar.
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